Trial Profile
Safety, Tolerability and Pharmacokinetics of a Single Subcutaneous Administration of SP16-a SERPIN-like, Small Peptide Agonist of the Low Density Lipoprotein-like Receptor 1-in Healthy Individuals
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Oct 2020
Price :
$35
*
At a glance
- Drugs SP-16 (Primary)
- Indications Diabetes mellitus; Inflammation; Myocardial infarction; Myocardial reperfusion injury
- Focus Adverse reactions
- Sponsors Serpin Pharma
- 21 Sep 2020 Status changed from active, no longer recruiting to completed.
- 13 Jan 2019 Planned primary completion date changed from 31 Dec 2018 to 2 Feb 2019.
- 13 Jan 2019 Status changed from recruiting to active, no longer recruiting.